Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5X7VY)

Drug Name
Pyrimethamine Drug Info
Synonyms
Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
Therapeutic ClassAntimalarials
Cross-matching ID
PubChem CID
4993
ChEBI ID
CHEMBL36
CAS Number
CAS 58-14-0
TTD Drug ID
D0C0SK
VARIDT Drug ID
DR01272
ACDINA Drug ID
D00573

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Allograft rejection 2.02 0.00e+0 32/38 (84.21%) CD40;HLA-DOB;HLA-F;...
Graft-versus-host disease 1.99 0.00e+0 32/42 (76.19%) HLA-DOB;HLA-F;HLA-DPB1;...
Type I diabetes mellitus 1.83 2.89e-2 38/43 (88.37%) HLA-DOB;HLA-F;HLA-DPB1;...
Glycine, serine and threonine metabolism 1.82 2.16e-2 31/40 (77.5%) PSAT1;CBS;SHMT2;...
Mismatch repair 1.78 3.90e-2 22/23 (95.65%) RFC5;PCNA;POLD4;...
Viral myocarditis 1.76 3.79e-2 53/60 (88.33%) CD40;HLA-DOB;HLA-F;...
Basal cell carcinoma 1.75 3.71e-2 41/63 (65.08%) DDB2;TP53;LEF1;...
Pertussis -1.67 4.99e-2 64/76 (84.21%) C4BPB;ITGB2;IL12B;...
Amoebiasis -1.72 4.79e-2 99/102 (97.06%) TNF;IL12A;TGFB3;...
mRNA surveillance pathway -1.85 8.87e-3 71/98 (72.45%) DAZAP1;PPP2CA;HBS1L;...
Ribosome biogenesis in eukaryotes -1.86 1.77e-2 52/108 (48.15%) MPHOSPH10;NOP56;CSNK2A2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 40uM 3H, 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H